Top Markets
Coin of the day
Lisata Therapeutics, Inc. Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

LSTA
Pozycja w akcjach #32451
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Cena akcji
$1.11
Kapitalizacja rynkowa
$10.06M
Zmiana (1 dzień)
1.38%
Zmiana (1 rok)
-56.32%
Kraj
US
Handel Lisata Therapeutics, Inc. (LSTA)

Kategoria

EPS dla Lisata Therapeutics, Inc. (LSTA)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy Lisata Therapeutics, Inc., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla Lisata Therapeutics, Inc. od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów